原发性硬化性胆管炎市场按药物类别、给药途径、分销管道和地区划分

2025 年全球原发性硬化性胆管炎市场规模估计为 1.741 亿美元，预计到 2032 年将达到 2.986 亿美元，2025 年至 2032 年的复合年增长率为 8.0%。

数字。 2025 年原发性硬化性胆管炎市场占有率（%），依地区划分

原发性硬化性胆管炎 (PSC) 是一种慢性进行性胆汁淤积性肝病，其特征是肝内和肝外胆管多灶性狭窄和纤维化。 70-80％的病例伴随发炎性肠道疾病肠道疾病，通常是溃疡性大肠炎。 PSC 的具体病因尚不清楚，但人们认为它是一种由遗传易感性和环境触发因素的复杂相互作用导致的自体免疫疾病。全球原发性硬化性胆管炎的盛行率估计为每十万人有13至16例。目前，PSC 尚无治疗方法，治疗重点是缓解症状和减缓病情进展。全球原发性硬化性胆管炎市场的成长是由诊断率的上升和医疗保健支出的增加所推动的。

市场动态

全球原发性硬化性胆管炎市场的成长受到多种因素的推动，例如人们对该疾病的认识不断提高、由于诊断方法的进步而导致的诊断率上升、以及全球易患原发性硬化性胆管炎的老年人口增加。然而，缺乏核准用于治疗 PSC 的药物和复杂的致病机制可能会阻碍市场的成长。正在进行的新疗法研发和新兴市场不断上升的医疗成本可能为市场参与企业创造巨大的商机。

研究的主要特点

本报告对全球原发性硬化性胆管炎市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。

它还揭示了各个领域的潜在商机并解释了该市场的引人注目的投资提案矩阵。

它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。

全球原发性硬化性胆管炎市场的主要企业根据公司亮点、产品系列、关键亮点、财务表现和策略等参数进行分析。

本研究涉及的主要企业包括 Intercept Pharmaceuticals、Dr. Falk Pharma GmbH 和 Acorda Therapeutics Inc.

本报告的见解将使负责人和公司经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。

全球原发性硬化性胆管炎市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员将透过全球原发性硬化性胆管炎市场分析中使用的各种策略矩阵来做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 监管情景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章 全球原发性硬化性胆管炎市场-冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020-2032 年全球原发性硬化性胆管炎市场（依药物类别划分）（百万美元）

• 介绍
• 熊去氧胆酸（UDCA）
• 皮质类固醇
• Azathioprine
• Mercaptopurine
• Budesonide
• 奥贝胆酸
• 单株抗体
• 其他的

6. 2020-2032 年全球原发性硬化性胆管炎市场，依给药途径划分（百万美元）

• 介绍
• 口服
• 肠外
• 其他的

7. 2020-2032 年全球原发性硬化性胆管炎市场按分销管道划分（百万美元）

• 介绍
• 医院药房
• 零售药局
• 网路药局

8. 2020 年至 2032 年全球原发性硬化性胆管炎市场（按地区划分）（百万美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章 竞争格局

• 公司简介
  • Acorda Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Dr. Falk Pharma GmbH
  • Allergan Plc.
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG

第 10 章分析师建议

• 兴衰
• 一致的机会地图

第 11 章 参考文献与调查方法

• 参考
• 调查方法

Global Primary Sclerosing Cholangitis Market is estimated to be valued at USD 174.1 Mn in 2025 and is expected to reach USD 298.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2032.

Figure. Primary Sclerosing Cholangitis Market Share (%), By Region 2025

Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease characterized by multifocal strictures and fibrosis of the intrahepatic and extrahepatic bile ducts. It is associated with inflammatory bowel disease, usually ulcerative colitis, in 70-80% of cases. The exact cause of PSC remains unknown, but it is believed to be an autoimmune disease resulting from a complex interplay between genetic susceptibility and environmental triggers. The global prevalence of PSC is estimated to range between 13-16 cases per 100,000 individuals. Currently, there is no cure for PSC and treatment is focused on relieving symptoms and slowing disease progression. Global primary sclerosing cholangitis market growth is driven by increasing diagnosis rates and rising healthcare expenditure.

Market Dynamics:

Global primary sclerosing cholangitis market growthis driven by factors like rising awareness about the disease, increasing diagnosis rates attributed to advanced diagnostic modalities, and growing geriatric population worldwide who are more susceptible to develop PSC. However, lack of an approved drug for treating PSC and complexities associated with the disease pathogenesis can hamper the market growth. Ongoing R&D for developing novel therapeutics and increasing healthcare expenditures in emerging nations can present high-impact profitable opportunities for market players.

Key Features of the Study:

This report provides in-depth analysis of the global primary sclerosing cholangitis market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global primary sclerosing cholangitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Intercept Pharmaceuticals, Dr. Falk Pharma GmbH, and Acorda Therapeutics Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary sclerosing cholangitis market

Detailed Segmentation-

• By Drug Class
  • Ursodeoxycholic acid (UDCA)
  • Corticosteroids
  • Azathioprine
  • Mercaptopurine
  • Budesonide
  • Obeticholic acid
  • Monoclonal antibody
  • Others
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Acorda Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Falk Pharma GmbH
  • Allergan Plc.
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Primary Sclerosing Cholangitis Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Primary Sclerosing Cholangitis Market, By Drug Class, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Ursodeoxycholic acid (UDCA)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Azathioprine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Mercaptopurine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Budesonide
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Obeticholic acid
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Monoclonal antibody
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Primary Sclerosing Cholangitis Market, By Route of Administration, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Primary Sclerosing Cholangitis Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Primary Sclerosing Cholangitis Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Acorda Therapeutics, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Gilead Sciences, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • NGM Biopharmaceuticals, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Intercept Pharmaceuticals, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dr. Falk Pharma GmbH
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Allergan Plc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact